Skip to content

Prediction Models for Complications After CRT in Esophageal Cancer

Prediction Models for Complications After CRT in Esophageal Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06366828
Acronym
MODELS
Enrollment
2000
Registered
2024-04-16
Start date
2023-02-01
Completion date
2030-06-30
Last updated
2024-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Aim of This Project is to Develop and Validate NTCP-models for Complications After nCRT (and Surgical Resection)

Keywords

prediction models, esophageal cancer (EC)

Brief summary

The aim of this project is to develop and validate NTCP-models for complications after nCRT (and surgical resection), that can be uses for model-based dose optimization for PhRT and PRT, and for model-based selection for PRT, in patients with esophageal cancer

Detailed description

Plan of investigation In the present project we aim to evaluate two potential strategies to predict and consider a broad spectrum of complications for radiotherapy plan optimization and patient selection: A comprehensive set of separate NTCP-models for several cardiopulmonary and post-operative complications after nCRT, which results in an NTCP-profile. A single multivariable NTCP-model for a so-called Complication Sum Score (CSS), which is a single composite complication endpoint including all complications after nCRT, weighted depending on severity and impact. These prediction models can be used for RT plan optimization and patient selection. In order to develop these prediction models the project consortium brings together existing prospective data registries for esophageal cancer, namely the Dutch Upper GI Cancer Audit (DUCA) and the Dutch Cancer Registry (NKR) (as well as the POCOP study). The data of these registries will be linked to a retrospective radiotherapy database using the ProTRAIT infrastructure, resulting in a dataset of over 2000 patients. In this retrospective cohort study, we will focus on esophageal cancer patients who were treated with nCRT, and for whom an esophagectomy was intended. We will include the patients who received nCRT and the esophagectomy in one of the participating centers. Patients who only received nCRT in one of the participating centers and for whom surgical resection was omitted will be included as well. Detailed eligibility criteria can be found in that section. Eligible patients will be identified by the Dutch Cancer Registry. The surviving patients will be asked to provide informed consent for participation in this study, permission to combine the different data registries and for future use of their data. Patients who died will be included as well, unless they objected agains the use of there data in the participating centers. Of the participating patients, the radiotherapy plan-CT and treatment plans (i.e. RTplan, RT struct, RT dose), will be pseudo-anonymized, uploaded and transferred to the UMCG data platform, by the participating radiotherapy centers. A third trusted party, Zorg TTP, will be responsible for the pseudonymization of the three data sources; the Dutch upper GI cancer audit (DUCA), the Dutch Cancer Registry (NKR) and the RTregistry. After that the linkage will be performed at the UMCG.

Interventions

follow up

Sponsors

Dutch Cancer Society
CollaboratorOTHER
Comprehensive Cancer Centre The Netherlands
CollaboratorOTHER
Dutch Institute for Clinical Auditing (DICA)
CollaboratorUNKNOWN
ZorgTTP
CollaboratorUNKNOWN
University Medical Center Groningen
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years

Inclusion criteria

* Tumor in the esophagus, histologically proven or suspect for esophageal carcinoma * WHO performance 0-2 * Age\>18years * No distant metastasis (M0) * Treated with nCRT and planned for or followed by an esophagectomy between 2015 and 2021 in one of the participating centers.

Exclusion criteria

* Sarcoma, neuro-endocrine or small cell carcinoma of the esophagus * Patients who underwent a surgical resection in a non-participating surgical center will be excluded

Design outcomes

Primary

MeasureTime frameDescription
Multivariable NTCP models will be developed for the prediction of the followingWithin 90 days after surgeryPostoperative complications (graded by ECCG classification (3) ): Atrial fibrillation ≥grade 2 Pneumonia ≥grade 2 Respiratory failure requiring re-intubation Anastomotic leakage ≥ grade 2
Cardiac events grade II or higher (CTCAE v 5.0), including:1 and 2 year after nCRTPericardial effusion Myocardial infarction and other acute coronary events Heart failure Pericardial effusion Myocardial infarction and other acute coronary events Heart failure Atrial fibrillation
Mortality1 and 2 year after nCRTMortality
Complication Sum Score, that will be determined in Delphi consensus1 year after nCRTComplication Sum Score, that will be determined in Delphi consensus

Secondary

MeasureTime frameDescription
Patient-rated nauseaUp to 30 day after nCRTPatient-rated nausea
Intensive care unit stay after esophagectomy (days)Intensive care unit stay after esophagectomy, average 1.5 daysIntensive care unit stay after esophagectomy (days)
Patient-rated fatigue / daily functioningUp to 6 months after nCRTPatient-rated fatigue / daily functioning
Patient-rated dysphagiaUp to 30 days after nCRTPatient-rated dysphagia
Hospitalization after esophagectomy (days)Hospitalization after esophagectomy, average 12 daysHospitalization after esophagectomy (days)

Countries

Netherlands

Contacts

Primary ContactChristina Muijs, Dr.
c.t.muijs@umcg.nl0503616161

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026